Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.